The United States Pharmacopeia (USP) has updated the vitamin K2 MK-7 analysis monograph to include a method of testing microencapsulated MK-7 powder.
The United States Pharmacopeia (USP) has updated the vitamin K2 MK-7 analysis monograph to include a method of testing microencapsulated MK-7 powder to reflect the growth of stability-enhanced K2, as well as reduce the risk of false-negative results and need for retesting. Vitamin K2 that is not stability-enhanced is not stable in high-alkaline formulations such as calcium and magnesium.
The new testing method was developed and submitted for approval by Kappa Biosciences (Oslo, Norway), which manufactures K2Vital Delta encapsulated vitamin K2. “Recognition of MK-7 encapsulation in the official analysis monograph is a significant milestone for vitamin K2,” said Inger Reidun Aukrust, developer of K2Vital Delta, and Kappa’s vice president of research and development, and chemistry, in a press release. “Microencapsulation solves the K2 minerals stability problem which prevents many products from meeting K2 label claim. Products that don't meet label claim can't deliver full health benefits and are not legal to sell. An official monograph that accounts for microencapsulation helps brands accurately monitor markets and ensure that consumer receive quality products.”